How should a newborn with congenital diaphragmatic hernia and tricuspid valve dysfunction be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Congenital Diaphragmatic Hernia with Tricuspid Valve Dysfunction in a Neonate

In a neonate with congenital diaphragmatic hernia (CDH) and tricuspid valve (TV) dysfunction, prioritize gentle lung-protective ventilation (tidal volumes 3.5-5 mL/kg), cautious use of pulmonary vasodilators only after establishing adequate left ventricular performance, and consider prostaglandin E1 infusion to maintain ductal patency for right-to-left shunting to support cardiac output in the setting of severe right ventricular dysfunction 1.

Critical Understanding: The Cardiac Dysfunction Problem

CDH is fundamentally a cardiopulmonary disease, not just a surgical problem. The presence of TV dysfunction compounds the already complex cardiac pathology inherent to CDH, which includes:

  • Left ventricular hypoplasia and dysfunction (systolic and diastolic)
  • Small LV cavity size
  • Right ventricular dysfunction from pulmonary hypertension
  • Impaired cardiac performance overall

The mortality rate for CDH with severe pulmonary hypertension reaches 45%, and TV dysfunction signals significant hemodynamic compromise 1.

Immediate Ventilatory Management

Primary Strategy: Lung-Protective Ventilation

Minimize peak inspiratory pressures and avoid large tidal volumes (Class I, Level of Evidence B) 1:

  • Target tidal volumes: 3.5-5 mL/kg (recognizing reduced functional residual capacity and total lung volume in CDH)
  • Accept permissive hypercapnia to avoid volutrauma
  • Avoid aggressive ventilation that worsens vascular injury

Escalation to High-Frequency Oscillatory Ventilation

HFOV is reasonable when conventional ventilation fails due to poor lung compliance, low volumes, and inadequate gas exchange (Class IIa, Level of Evidence A) 1.

Management of Pulmonary Hypertension with Cardiac Dysfunction

The Critical Caveat: Pulmonary Vasodilators and LV Dysfunction

Do NOT routinely use inhaled nitric oxide (iNO) in CDH 1. This is fundamentally different from standard PPHN management because:

  • RCTs showed iNO had no effect on death or ECMO use in CDH
  • One trial showed increased ECMO use with iNO treatment
  • The mechanism of failure: Lowering pulmonary vascular resistance increases preload to an already dysfunctional LV that cannot handle increased stroke volume, resulting in pulmonary venous hypertension and pulmonary edema

When to Consider iNO (Selective Use Only)

iNO should be limited to patients with (Class IIa, Level of Evidence B) 1:

  • Suprasystemic pulmonary vascular resistance
  • Right-to-left shunting across the foramen ovale causing critical preductal hypoxemia
  • After optimal lung inflation is achieved
  • After adequate LV performance is confirmed by echocardiography

iNO may stabilize patients before ECMO cannulation, improving safety of the procedure 1.

Specific Management for TV Dysfunction

Prostaglandin E1 Strategy

Consider prostaglandin E1 infusion (Class IIb, Level of Evidence C) for 1:

  • Suprasystemic levels of pulmonary hypertension
  • RV failure compromising cardiac output
  • Severe LV dysfunction

Rationale: Maintains ductal patency to enhance right-to-left ductal shunting, augmenting the RV's ability to maintain cardiac output by bypassing the pulmonary circulation when the ventricle cannot effectively pump against high pulmonary pressures.

Inotropic Support

Intravenous milrinone is reasonable for LV dysfunction (Class IIa, Level of Evidence B) 1. Given that CDH characteristically involves LV dysfunction and you have additional TV dysfunction:

  • Milrinone provides both inotropic support and pulmonary vasodilation
  • May be superior to pure vasodilators in this context
  • Monitor closely for systemic hypotension

Adjunctive Therapies (Use Cautiously)

Sildenafil may augment pulmonary vasodilation effects if iNO is used, but evidence is limited in CDH specifically (Class IIa for refractory PPHN, but extrapolate cautiously to CDH) 1.

Echocardiographic Assessment

Perform early, detailed cardiac evaluation 2, 3:

  • Assess LV size, systolic and diastolic function
  • Quantify TV regurgitation severity
  • Estimate pulmonary artery pressure
  • Evaluate RV function and size
  • Identify any structural cardiac anomalies
  • Repeat serially to guide therapy adjustments

Targeted neonatal echocardiography can be performed quickly (mean 26 minutes) and safely within hours of birth 3.

ECMO Considerations

ECMO is indicated for severe pulmonary hypertension or hypoxemia refractory to medical therapy (Class I, Level of Evidence B) 1:

  • The presence of TV dysfunction may lower the threshold for ECMO consideration
  • Cardiac dysfunction is associated with poor outcomes and increased mortality 2
  • Configuration selection (VA vs VV) should involve multidisciplinary discussion, with VA-ECMO providing better cardiac support

Timing of Surgical Repair

For high-risk patients (including those with significant cardiac dysfunction): Consider early repair on ECMO 2, 4:

  • Early repair during ECMO course appears to improve mortality
  • Allows physiologic stabilization before repair
  • The traditional approach of delayed repair may not apply to high-risk cases

For anticipated short ECMO runs in lower-risk patients: Delayed repair post-ECMO may be appropriate 2.

Common Pitfalls to Avoid

  1. Do not treat CDH like standard PPHN: The cardiac pathology fundamentally changes the response to pulmonary vasodilators
  2. Do not aggressively vasodilate without confirming LV function: Risk worsening pulmonary edema
  3. Do not delay ECMO in severe cardiac dysfunction: Mortality increases with prolonged medical management failure
  4. Do not use routine iNO: Reserve for highly selected cases only
  5. Do not overlook the TV dysfunction: This signals severe hemodynamic compromise requiring aggressive support

Monitoring and Ongoing Assessment

  • Continuous preductal and postductal oxygen saturation monitoring
  • Arterial blood gases with permissive hypercapnia (PaCO2 45-60 mmHg acceptable)
  • Serial echocardiograms to assess response to therapy
  • Oxygenation index calculation if considering escalation
  • Close hemodynamic monitoring for signs of low cardiac output

Long-term Considerations

Even after initial stabilization, these infants require:

  • Longitudinal care in interdisciplinary pediatric pulmonary hypertension programs (Class I, Level of Evidence B) 1
  • Annual echocardiography to monitor for persistent or late-developing pulmonary hypertension
  • Cardiac catheterization may be needed to diagnose pulmonary arterial and venous structural abnormalities 1

The combination of CDH with TV dysfunction represents one of the highest-risk presentations, requiring immediate involvement of neonatology, pediatric cardiology, cardiac surgery, and ECMO teams for optimal outcomes.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.